{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T22:01:44Z","timestamp":1791928904635,"version":"4.3.4"},"reference-count":51,"publisher":"Association for Research in Vision and Ophthalmology (ARVO)","issue":"4","license":[{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Invest. Ophthalmol. Vis. Sci."],"published-print":{"date-parts":[[2026,4,21]]},"DOI":"10.1167\/iovs.67.4.47","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T13:30:44Z","timestamp":1776778244000},"page":"47","source":"Crossref","is-referenced-by-count":0,"title":["Safety and Efficacy of cceAAV-aflibercept-Fc-YTE (F-CRG-B191): A Gene Therapy for Neovascular Age-Related Macular Degeneration"],"prefix":"10.1167","volume":"67","author":[{"given":"Jiemei","family":"Shi","sequence":"first","affiliation":[{"name":"Department of Ophthalmology and Vision Science, Eye and ENT Hospital, Fudan University, Shanghai, China"},{"name":"Key Laboratory of Myopia and Related Eye Diseases, NHC, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Vision Science, Eye and ENT Hospital, Fudan University, Shanghai, China"},{"name":"Key Laboratory of Myopia and Related Eye Diseases, NHC, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongmei","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Vision Science, Eye and ENT Hospital, Fudan University, Shanghai, China"},{"name":"Key Laboratory of Myopia and Related Eye Diseases, NHC, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajie","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Vision Science, Eye and ENT Hospital, Fudan University, Shanghai, China"},{"name":"Key Laboratory of Myopia and Related Eye Diseases, NHC, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihui","family":"Chen","sequence":"additional","affiliation":[{"name":"Shanghai Correge Pharmaceutical Technology Co., Ltd., Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Xu","sequence":"additional","affiliation":[{"name":"Shanghai Correge Pharmaceutical Technology Co., Ltd., Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Jia","sequence":"additional","affiliation":[{"name":"Shanghai Correge Pharmaceutical Technology Co., Ltd., Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunhui","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Vision Science, Eye and ENT Hospital, Fudan University, Shanghai, China"},{"name":"Key Laboratory of Myopia and Related Eye Diseases, NHC, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"27","reference":[{"key":"bib1","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1001\/jama.2023.26074","article-title":"Age-related macular degeneration: a review","volume":"331","author":"Fleckenstein","year":"2024","journal-title":"JAMA"},{"key":"bib2","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.3390\/ijms22031170","article-title":"Neovascular macular degeneration: a review of etiology, risk factors, and recent advances in research and therapy","volume":"22","author":"Pugazhendhi","year":"2021","journal-title":"Int J Mol Sci"},{"key":"bib3","doi-asserted-by":"publisher","first-page":"252","DOI":"10.3390\/biom14030252","article-title":"Treatment strategies for anti-VEGF resistance in neovascular age-related macular degeneration by targeting arteriolar choroidal neovascularization","volume":"14","author":"Fu","year":"2024","journal-title":"Biomolecules"},{"key":"bib4","doi-asserted-by":"publisher","first-page":"8242","DOI":"10.3390\/ijms21218242","article-title":"Neovascular age-related macular degeneration: therapeutic management and new-upcoming approaches","volume":"21","author":"Ricci","year":"2020","journal-title":"Int J Mol Sci"},{"key":"bib5","doi-asserted-by":"publisher","first-page":"943915","DOI":"10.3389\/fbioe.2022.943915","article-title":"Application and mechanism of anti-VEGF drugs in age-related macular degeneration","volume":"10","author":"Song","year":"2022","journal-title":"Front Bioeng Biotechnol"},{"key":"bib6","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","article-title":"Adeno-associated virus vector as a platform for gene therapy delivery","volume":"18","author":"Wang","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"bib7","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1089\/hum.2018.144","article-title":"Dosage thresholds and influence of transgene cassette in adeno-associated virus-related toxicity","volume":"29","author":"Khabou","year":"2018","journal-title":"Hum Gene Ther"},{"key":"bib8","doi-asserted-by":"publisher","first-page":"101206","DOI":"10.1016\/j.omtm.2024.101206","article-title":"A novel class of self-complementary AAV vectors with multiple advantages based on cceAAV lacking mutant ITR","volume":"32","author":"Zhang","year":"2024","journal-title":"Mol Ther Methods Clin Dev"},{"key":"bib9","doi-asserted-by":"publisher","first-page":"4997","DOI":"10.1167\/iovs.16-21283","article-title":"Inhibition of placenta growth factor reduces subretinal mononuclear phagocyte accumulation in choroidal neovascularization","volume":"58","author":"Crespo-Garcia","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"bib10","doi-asserted-by":"publisher","first-page":"9700","DOI":"10.1038\/s41598-024-60540-6","article-title":"Sphingosine-1-phosphate receptor 1\/5 selective agonist alleviates ocular vascular pathologies","volume":"14","author":"Nakamura","year":"2024","journal-title":"Sci Rep"},{"key":"bib11","doi-asserted-by":"publisher","first-page":"e0278951","DOI":"10.1371\/journal.pone.0278951","article-title":"Assessment of mouse VEGF neutralization by ranibizumab and aflibercept","volume":"17","author":"Ichiyama","year":"2022","journal-title":"PLoS One"},{"key":"bib12","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1038\/nprot.2013.135","article-title":"Laser-induced choroidal neovascularization model to study age-related macular degeneration in mice","volume":"8","author":"Lambert","year":"2013","journal-title":"Nat Protoc"},{"key":"bib13","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1001\/archophthalmol.2011.210","article-title":"Prevention of experimental choroidal neovascularization and resolution of active lesions by VEGF trap in nonhuman primates","volume":"129","author":"Nork","year":"2011","journal-title":"Arch Ophthalmol"},{"key":"bib14","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1016\/j.ajpath.2015.04.029","article-title":"Novel CCR3 antagonists are effective mono- and combination inhibitors of choroidal neovascular growth and vascular permeability","volume":"185","author":"Nagai","year":"2015","journal-title":"Am J Pathol"},{"key":"bib15","doi-asserted-by":"publisher","first-page":"3780","DOI":"10.1038\/s41467-024-48221-4","article-title":"An adeno-associated virus variant enabling efficient ocular-directed gene delivery across species","volume":"15","author":"Luo","year":"2024","journal-title":"Nat Commun"},{"key":"bib16","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1167\/iovs.66.2.11","article-title":"Retinal and choriocapillaris thickness changes in spontaneously diabetic macaques","volume":"66","author":"Zhou","year":"2025","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"bib17","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1016\/S0140-6736(15)00345-1","article-title":"Gene therapy with recombinant adeno-associated vectors for neovascular age-related macular degeneration: 1 year follow-up of a phase 1 randomised clinical trial","volume":"386","author":"Rakoczy","year":"2015","journal-title":"Lancet"},{"key":"bib18","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.ophtha.2013.08.035","article-title":"Intravitreal aflibercept for treatment-resistant neovascular age-related macular degeneration","volume":"121","author":"Chang","year":"2014","journal-title":"Ophthalmology"},{"key":"bib19","doi-asserted-by":"publisher","first-page":"6816","DOI":"10.1038\/s41598-021-86348-2","article-title":"High frequency SD-OCT follow-up leading to up to biweekly intravitreal ranibizumab treatment in neovascular age-related macular degeneration","volume":"11","author":"Tuerksever","year":"2021","journal-title":"Sci Rep"},{"key":"bib20","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1002\/lsm.22531","article-title":"The short-term effects of aflibercept on the size of choroidal neovascularization lesion in treatment-resistant neovascular age-related macular degeneration as determined by spectral-domain optical coherence tomography","volume":"48","author":"Abri","year":"2016","journal-title":"Lasers Surg Med"},{"key":"bib21","doi-asserted-by":"publisher","first-page":"3308","DOI":"10.1016\/j.ymthe.2023.09.019","article-title":"Preclinical evaluation of KH631, a novel rAAV8 gene therapy product for neovascular age-related macular degeneration","volume":"31","author":"Ke","year":"2023","journal-title":"Mol Ther"},{"key":"bib22","doi-asserted-by":"publisher","first-page":"786870","DOI":"10.1155\/2012\/786870","article-title":"Anti-VEGF treatment strategies for wet AMD","volume":"2012","author":"Kovach","year":"2012","journal-title":"J Ophthalmol"},{"key":"bib23","doi-asserted-by":"publisher","first-page":"102394","DOI":"10.1016\/j.eclinm.2023.102394","article-title":"Safety and efficacy of ixoberogene soroparvovec in neovascular age-related macular degeneration in the united states (OPTIC): a prospective, two-year, multicentre phase 1 study","volume":"67","author":"Khanani","year":"2024","journal-title":"EClinicalMedicine"},{"key":"bib24","doi-asserted-by":"publisher","first-page":"720","DOI":"10.3390\/genes15060720","article-title":"Gene therapy for non-hereditary retinal disease: age-related macular degeneration, diabetic retinopathy, and beyond","volume":"15","author":"Rowe","year":"2024","journal-title":"Genes (Basel)"},{"key":"bib25","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1016\/S0140-6736(24)00310-6","article-title":"Gene therapy for neovascular age-related macular degeneration by subretinal delivery of RGX-314: a phase 1\/2a dose-escalation study","volume":"403","author":"Campochiaro","year":"2024","journal-title":"Lancet"},{"key":"bib26","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1089\/hum.2015.130","article-title":"Cone-specific promoters for gene therapy of achromatopsia and other retinal diseases","volume":"27","author":"Ye","year":"2016","journal-title":"Hum Gene Ther"},{"key":"bib27","doi-asserted-by":"publisher","first-page":"e0148874","DOI":"10.1371\/journal.pone.0148874","article-title":"AAV-mediated clarin-1 expression in the mouse retina: implications for USH3a gene therapy","volume":"11","author":"Dinculescu","year":"2016","journal-title":"PLoS One"},{"key":"bib28","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.bbrc.2019.05.117","article-title":"Gene delivery to cone photoreceptors by subretinal injection of rAAV2\/6 in the mouse retina","volume":"515","author":"Hori","year":"2019","journal-title":"Biochem Biophys Res Commun"},{"key":"bib29","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1136\/bjo.2007.134874","article-title":"Predicted biological activity of intravitreal VEGF trap","volume":"92","author":"Stewart","year":"2008","journal-title":"Br J Ophthalmol"},{"key":"bib30","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1097\/IAE.0000000000002566","article-title":"Pharmacokinetic study of intravitreal aflibercept in humans with neovascular age-related macular degeneration","volume":"40","author":"Do","year":"2020","journal-title":"Retina"},{"key":"bib31","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.ajo.2008.05.036","article-title":"Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans","volume":"146","author":"Krohne","year":"2008","journal-title":"Am J Ophthalmol"},{"key":"bib32","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1016\/j.molimm.2009.01.026","article-title":"Structural characterization of a human fc fragment engineered for extended serum half-life","volume":"46","author":"Oganesyan","year":"2009","journal-title":"Mol Immunol"},{"key":"bib33","doi-asserted-by":"publisher","first-page":"5171","DOI":"10.4049\/jimmunol.169.9.5171","article-title":"Increasing the affinity of a human IgG1 for the neonatal fc receptor: biological consequences","volume":"169","author":"Dall'Acqua","year":"2002","journal-title":"J Immunol"},{"key":"bib34","doi-asserted-by":"publisher","first-page":"100827","DOI":"10.1016\/j.preteyeres.2019.100827","article-title":"Progress in treating inherited retinal diseases: early subretinal gene therapy clinical trials and candidates for future initiatives","volume":"77","author":"Garafalo","year":"2020","journal-title":"Prog Retin Eye Res"},{"key":"bib35","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1080\/08830180212066","article-title":"Anterior chamber associated immune deviation (ACAID): regulation, biological relevance, and implications for therapy","volume":"21","author":"Stein-Streilein","year":"2002","journal-title":"Int Rev Immunol"},{"key":"bib36","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/mt.2010.258","article-title":"Preclinical safety evaluation of AAV2-sFLT01\u2014a gene therapy for age-related macular degeneration","volume":"19","author":"Maclachlan","year":"2011","journal-title":"Mol Ther"},{"key":"bib37","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(18)31550-2","article-title":"Age-related macular degeneration","volume":"392","author":"Mitchell","year":"2018","journal-title":"Lancet"},{"key":"bib38","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1097\/APO.0000000000000291","article-title":"Emerging therapies in neovascular age-related macular degeneration in. 2020","volume":"9","author":"Samanta","year":"2020","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"key":"bib39","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.omtm.2019.08.011","article-title":"Safety of same-eye subretinal sequential readministration of AAV2-hRPE65v2 in non-human primates","volume":"15","author":"Weed","year":"2019","journal-title":"Mol Ther Methods Clin Dev"},{"key":"bib40","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1001\/archophthalmol.2011.295","article-title":"Functional and anatomic consequences of subretinal dosing in the cynomolgus macaque","volume":"130","author":"Nork","year":"2012","journal-title":"Arch Ophthalmol"},{"key":"bib41","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1097\/00006982-199414020-00014","article-title":"Retinal adhesiveness in surgically enucleated human eyes","volume":"14","author":"Marmor","year":"1994","journal-title":"Retina"},{"key":"bib42","doi-asserted-by":"publisher","first-page":"984523","DOI":"10.3389\/fendo.2022.984523","article-title":"Analysis of serum bone turnover markers in female cynomolgus monkeys of different ages","volume":"13","author":"Li","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"bib43","first-page":"63","article-title":"Aqueous protein concentration in rhegmatogenous retinal detachment","volume":"34","author":"Oshika","year":"1990","journal-title":"Jpn J Ophthalmol"},{"key":"bib44","doi-asserted-by":"crossref","first-page":"6940625","DOI":"10.1155\/2020\/6940625","article-title":"Silicone oil emulsification after vitrectomy for rhegmatogenous retinal detachment","volume":"2020","author":"Yu","year":"2020","journal-title":"J Ophthalmol"},{"key":"bib45","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.omtm.2022.01.002","article-title":"Delivery of nVEGFi using AAV8 for the treatment of neovascular age-related macular degeneration","volume":"24","author":"She","year":"2022","journal-title":"Mol Ther Methods Clin Dev"},{"key":"bib46","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1016\/j.ymthe.2006.03.005","article-title":"Safety of recombinant adeno-associated virus type 2-RPE65 vector delivered by ocular subretinal injection","volume":"13","author":"Jacobson","year":"2006","journal-title":"Mol Ther"},{"key":"bib47","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.omtm.2017.12.001","article-title":"Nonclinical safety evaluation of scAAV8-RLBP1 for treatment of RLBP1 retinitis pigmentosa","volume":"8","author":"Maclachlan","year":"2018","journal-title":"Mol Ther Methods Clin Dev"},{"key":"bib48","doi-asserted-by":"publisher","first-page":"e111569","DOI":"10.1371\/journal.pone.0111569","article-title":"Standardized full-field electroretinography in the green monkey (Chlorocebus sabaeus)","volume":"9","author":"Bouskila","year":"2014","journal-title":"PLoS One"},{"key":"bib49","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.omtn.2022.04.015","article-title":"CRISPR-based VEGF suppression using paired guide RNAs for treatment of choroidal neovascularization","volume":"28","author":"Chung","year":"2022","journal-title":"Mol Ther Nucleic Acids"},{"key":"bib50","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1016\/j.ophtha.2011.03.020","article-title":"The 1-year results of CLEAR-IT 2, a phase 2 study of vascular endothelial growth factor trap-eye dosed as-needed after 12-week fixed dosing","volume":"118","author":"Heier","year":"2011","journal-title":"Ophthalmology"},{"key":"bib51","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.ymthe.2018.11.003","article-title":"Preclinical evaluation of ADVM-022, a novel gene therapy approach to treating wet age-related macular degeneration","volume":"27","author":"Grishanin","year":"2019","journal-title":"Mol Ther"}],"container-title":["Investigative Ophthalmology & Visual Science"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/iovs.arvojournals.org\/article.aspx?doi=10.1167\/iovs.67.4.47","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:32:20Z","timestamp":1791927140000},"score":1,"resource":{"primary":{"URL":"http:\/\/iovs.arvojournals.org\/article.aspx?doi=10.1167\/iovs.67.4.47"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,21]]},"references-count":51,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4,1]]}},"URL":"https:\/\/doi.org\/10.1167\/iovs.67.4.47","relation":{},"ISSN":["1552-5783"],"issn-type":[{"value":"1552-5783","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4,21]]}}}